Beacon Intelligence is a drug development intelligence platform providing data, analytics and workflow tools to pharmaceutical and biotechnology companies. The acquisition will support Beacon’s next phase of growth as an independent business, with Corten Capital becoming the majority owner and Ampersand investing as a minority co-investor.

The Hogan Lovells Cadwalader team was led by London Banking & Loan Finance partner Francis Booth with support from senior associate Alistair Handy, associate Ashali Herai and trainee solicitor Julie Levert-Cui.